OncoMatch/Clinical Trials/NCT05901519
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Is NCT05901519 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Prednisone for hepatocellular carcinoma.
Treatment: Prednisone — Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Liver function
ALBI score equal to (-1.81) or higher (worse); CP score equal to 7 or higher (worse); decompensated liver disease (clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage) excluded
ALBI score equal to (-1.81) or higher (worse). CP score equal to 7 or higher (worse). Decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rogel Comprehensive Cancer Center · Ann Arbor, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05901519 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages